Next Article in Journal
Calcified Neurocysticercosis: Demographic, Clinical, and Radiological Characteristics of a Large Hospital-Based Patient Cohort
Next Article in Special Issue
Genomic Features of an MDR Escherichia coli ST5506 Harboring an IncHI2/In229/blaCTX-M-2 Array Isolated from a Migratory Black Skimmer
Previous Article in Journal
AEN Suppresses the Replication of Porcine Epidemic Diarrhea Virus by Inducing the Expression of Type I IFN and ISGs in MARC-145 Cells
Previous Article in Special Issue
Genomic Insights into Pluralibacter gergoviae Sheds Light on Emergence of a Multidrug-Resistant Species Circulating between Clinical and Environmental Settings
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Clonal Diversity, Antibiotic Resistance, and Virulence Factor Prevalence of Community Associated Staphylococcus aureus in Southeastern Virginia

1
Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
2
School of Health Professions, Eastern Virginia Medical School, Norfolk, VA 23507, USA
3
Children’s Hospital of the King’s Daughters, Norfolk, VA 23507, USA
*
Author to whom correspondence should be addressed.
Pathogens 2024, 13(1), 25; https://doi.org/10.3390/pathogens13010025
Submission received: 18 November 2023 / Revised: 13 December 2023 / Accepted: 19 December 2023 / Published: 27 December 2023
(This article belongs to the Special Issue Detection and Epidemiology of Drug-Resistant Bacteria)

Abstract

:
Staphylococcus aureus is a significant human pathogen with a formidable propensity for antibiotic resistance. Worldwide, it is the leading cause of skin and soft tissue infections (SSTI), septic arthritis, osteomyelitis, and infective endocarditis originating from both community- and healthcare-associated settings. Although often grouped by methicillin resistance, both methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) strains are known to cause significant pathologies and injuries. Virulence factors and growing resistance to antibiotics play major roles in the pathogenicity of community-associated strains. In our study, we examined the genetic variability and acquired antibiograms of 122 S. aureus clinical isolates from SSTI, blood, and urinary tract infections originating from pediatric patients within the southeast region of Virginia, USA. We identified a suite of clinically relevant virulence factors and evaluated their prevalence within these isolates. Five genes (clfA, spA, sbi, scpA, and vwb) with immune-evasive functions were identified in all isolates. MRSA isolates had a greater propensity to be resistant to more antibiotics as well as significantly more likely to carry several virulence factors compared to MSSA strains. Further, the carriage of various genes was found to vary significantly based on the infection type (SSTI, blood, urine).

1. Introduction

Staphylococcus aureus causes a multitude of infections that affect various bodily systems, including the skin and soft structure, bone, joints, heart, bacteremia, and implant- or surgical site-affiliated infections [1,2]. Whilst healthcare-associated (HA) infections are often the focus of preventative measures imposed by care facilities and hospitals, community-associated (CA) infections, which originate outside of a healthcare setting, remain a significant contributor to the overall burden of S. aureus on healthcare systems worldwide [3,4,5,6]. Both its persistence within environmental and animal reservoirs [2,7,8], as well as a high rate of benign carriage within most healthy populations (about 30%) [2,9], contribute to this ongoing threat to community health. In recent years, the rate of infection by methicillin resistant S. aureus (MRSA) has decreased, stabilizing increases seen in the late 1990s to early 2000s [4,10], with a shift in concern to vancomycin and clindamycin resistance currently [11,12,13,14,15]. MRSA infections remain a significant source of disease worldwide, particularly within vulnerable populations. Risk factors include previous hospital stays, catheterization, advanced age or infancy, intravenous drug use, being of an ethnic minority, or lower socioeconomic status [3,4,5,6,16].
S. aureus wields a plethora of virulence factors (VFs) designed to facilitate infection and cause disease. To survive within the host environment, S. aureus adheres to host surfaces, utilizes host elements for metabolic needs, and subverts host immunity through a variety of VFs. The complement system, operating through a catalytic cascade, plays a significant role in the host innate defense by labeling pathogens as foreign (opsonization), lysing susceptible cells, and actively recruiting effector cells for pathogen clearance. As such, the complement system and its various components are primary targets of S. aureus VFs [17].
Adhesins, which allow S. aureus to bind to a host substrate and promote biofilm development, can be subdivided into cell wall-bound MSCRAMMs (microbial surface components recognizing adhesive matrix molecules) and secreted SERAMs (secretable expanded repertoire adhesive molecules). MSCRAMMs have at least two IgG-like folds and a “dock, lock, and latch” mechanism for binding to ligands (reviewed in [18]). SERAMs mediate bacterial adhesion with host components (such as cells, molecules, or tissues), whilst also interfering with host defense mechanisms [19].
Secreted proteins, which are actively released away from the bacterium, can harm the host by affecting host immunity [20]. SCIN (staphylococcal complement inhibitor, scn) and CHIPS (Chemotaxis inhibitory protein of S. aureus, chp) negatively affect the progress of complement by impeding the activity of complement-associated enzymes [21] or phagocyte recruitment, respectively [22,23]. Panton Valentine Leukocidin (pvl), a well-known toxin that targets immune cells directly, forms β-barrel pores, resulting in cellular lysis and the subsequent death of phagocytes [24].
Many S. aureus VFs are multifunctional and have additional—or often redundant—roles. For example, ClfA (clumping factor A) and SdrE (serine aspartate repeat protein E) belong to the MSCRAMM family of adhesins, yet also participate in immune evasion by binding host complement regulators to subvert complement-mediated opsonization on the S. aureus surface [25,26]. Both staphylococcal Protein A (spA) and staphylococcal binder of immunoglobulin (sbi) bind antibody by the Fc region [27] and can be surface-bound or secreted. Thus, functional redundancies and/or multipurpose VFs create challenges for elucidating the role of VFs and specific disease manifestations. However, in the context of toxin-related diseases, some causative genes have been identified, such as eta/etb (staphylococcal scalded skin syndrome [28]) and tsst-1 (toxic shock syndrome) [29]. Further, some VFs are designated as risk factors for specific infections, such as bbp in osteomyelitis [30], and pvl in osteomyelitis, lung infection, and severe infections [30,31,32]. Evidence also suggests that the presence of pvl or tsst-1 may indicate elevated antibiotic resistance [33,34]. Thus, determining VF-associated gene carriage in clinical isolates will shed light on the potential for S. aureus to cause disease.
As such, we sought to gain a better understanding of S. aureus virulence potential in isolates associated with communities of Southeastern Virginia. Using whole-genomic sequencing and targeted genomics, we screened 122 clinical isolates collected from patients of a children’s hospital in Norfolk, VA USA, to characterize lineage information (clonal complex and sequence type) as well as the carriage of a panel of clinically relevant VF-associated genes (Table 1). These data were analyzed against identified drug resistance/sensitivity profiles from isolate-specific antibiogram data. Infection type and methicillin resistance/sensitivity were used as additional discriminators to examine the relationship between lineage, VF gene carriage, and antibiotic resistance. Thus, this study provides information on VF prevalence and their association with infection type or antibiotic resistance and identifies common pathogenic determinants to support the development of targeted treatment strategies.

2. Materials and Methods

2.1. Bacteria

Community-associated S. aureus isolates were obtained as de-identified, discarded specimens from a children’s hospital in Norfolk, VA, and transferred in accordance with IRB 18-05-EX-0109; no human samples were used in this study. Isolates were identified as S. aureus via matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry using the MALDI Biotyper Sirius CA System. Characterization of antibiotic resistance or sensitivity was determined using BD Phoenix PMIC 109 panel, a broth microdilution method utilizing cation-adjusted BD broth with 2-fold serial dilutions, and read every 20 min up to 16 h. Clinical and Laboratory Standards Institute and Antimicrobial Susceptibility Testing (CLSI AST) guideline rules were applied for validation, with six reference strains (S. aureus ATCC 29213, 25923, BAA-976 and BAA-977; Enterococcus faecalis ATCC 29212 and 51299) for quality control. See Table 2 for associated antibiotics and applied ranges. Isolates with demonstrated resistance or sensitivity to oxacillin were considered to be MRSA or MSSA, respectively. Infections of the blood or urine were deemed invasive due to infection location. SSTI infections were not classified as invasive or superficial.

2.2. DNA Extraction

Isolates were cultured on Columbia agar (BD Difco, Franklin Lakes, NJ, USA) with 2% NaCl. Bacteria were resuspended in sterile deionized water then heated at 99 °C for 10 min to lyse the cells. Lysates were subjected to phase extraction with phenol/chloroform/isoamyl alcohol, 25:24:1 (Sigma-Aldrich, St. Louis, MO, USA), followed by ethanol precipitation, and washed with 70% ethanol to purify gDNA. Concentration and purity of gDNA were assessed with a Nanodrop spectrophotometer or Qubit 4 fluorometer. gDNA samples were stored at −80 °C until use.

2.3. Whole-Genome Sequencing and Assembly

gDNA samples were prepared using the Illumina DNA LP (M) Tagmentation and Nextera DNA CD index kits, per manufacturer’s instructions. Prepared samples were subjected to whole-genome sequencing (WGS) using the Illumina iSeq 100 system, with paired-end read length of 150 bp and depth of 30× reads. Assembly of contigs was accomplished with the Assembly module of the Local Run Manager (Illumina, San Diego, CA, USA), which contains onboard algorithms for error correction and quality control of raw sequence reads. Genome annotation was performed using the Prokka prokaryotic genome annotation software (Version 1.14.6) [57], available via the Galaxy Project. Individual gene searches were conducted using the NIH NCBI database BLAST tool.

2.4. Sanger Sequencing and PCR

Clonal complex (CC) and sequence type (ST) were determined using WGS contigs screened via the PubMLST database [58]. For reads in dispute, Sanger sequencing was performed (EVMS Molecular Core Facility) as previously described [59]. MRSA isolates were further characterized for SCCmec type using multiplex PCR, as described by Zhang, et al. [60,61]. For unsuccessful WGS (n = 2, blood), gDNA was investigated for select VF presence by end-point PCR (Table 3).

2.5. Statistics

Statistical analyses were performed using R (Version 4.2.3) and the packages “readxl”, “dplyr”, “ggplot2” and “ggcorrplot” [69,70,71,72,73]. The associations between categorical data were evaluated using Fisher’s exact test with the addition of Mehta and Patel’s (1985) hybrid algorithm [74]. We evaluated the relationships between the antibiograms and the infection type or methicillin resistance using chi-squared tests. We ran appropriate nonparametric tests for the response variables that exhibit non-normal characteristics. All statistical tests of inferences were assessed at the 5% alpha level.

3. Results

3.1. Sample Pool Composition

The isolate pool included in this study is depicted in Figure 1 and described in Table 4, categorized by infection type and methicillin resistance/sensitivity (n = 122). In total, 44% of sequenced isolates were MRSA (n = 54), and 56% were MSSA (n = 68), with most isolates from SSTI, followed by blood, then urinary tract infections. Two blood MRSA isolates were characterized using Sanger sequencing and end-point PCR for select VF genes, due to unsuccessful WGS runs.

3.2. Sequence Type, Clonal Complex, and SCCmec Distribution

To understand the lineage composition of the isolate pool (n = 122), we performed genomic analysis, revealing 31 unique sequence types (ST) within 9 recognized and 12 unknown/unrecognized clonal complexes (CCs). The most common lineage was CC 8 and ST 8; however, CC 8 isolates also represented the STs 72, 1159, 1181, 2176, and 7361 [58]. STs with low representation comprised 34 isolates, with 9 CA-MRSA and 25 CA-MSSA belonging to an additional 7 and 19 STs, respectively, and 3 additional CCs. See Supplementary Materials for a complete tally.
As the pool contained both MRSA and MSSA, we used methicillin resistance as a discriminator, indicating a significant relationship for CC and ST distribution (Figure 2A,B). A selection of four CCs and their corresponding STs (excluding urine isolates) were further analyzed to determine the direction of the significance (Figure 2C,D). Significance was retained for both CC and ST (p < 0.01).
To determine whether infection type was a significant factor in lineage, we analyzed infection type with CC or ST. Whilst most isolates were from SSTI and belonged to CC 8 (as well as ST 8)—see Figure 3A,B—a significant relationship was found between infection type and CC or ST (p = 0.048, p < 0.01, respectively); however, the categories contributing to this test statistic are unknown. To further investigate this relationship, we examined the four most well represented CC and corresponding ST (excluding urine); see Figure 3C,D. However, no significant relationship was determined (p = 0.1214).
As an additional feature relevant for characterizing the MRSA isolates, we examined the distribution of SCCmec (Figure 4), which demonstrated SCCmec type IVa to be dominant (77.8%). Four MRSA isolates were untypeable and may belong to an unknown type or those outside the tested type I–V distribution.

3.3. Antibiogram Data

Antibiotic resistance is summarized in Figure 5. More than half of the pool (58%) were resistant to erythromycin (81% of MRSA, 40% of MSSA; p < 0.01, Χ2 = 16.797, df = 1); Figure 5A. Clindamycin resistance was equally distributed between MRSA and MSSA at 13%. Tetracycline resistance was present in 7% of isolates, and slightly more common in MRSA strains than MSSA (7% vs. 6%, respectively). Trimethoprim-sulfamethoxazole (TMP-SMZ) and gentamycin resistance were less common, with TMP-SMZ resistance evident in 5% (6% of MSSA, 4% of MRSA) and gentamycin resistance in 2% (MSSA). No significant difference in antibiotic resistance was determined based on infection type, blood vs. SSTI; however, clindamycin and erythromycin resistance were higher in isolates from blood infections vs. SSTI (Figure 5B). With the exception of penicillin, all urine samples were sensitive to the entire antibiotic panel. Excluding oxacillin and penicillin, MRSA isolates were found to have significantly higher average resistances (1.09 antibiotics/isolate) than the MSSA isolates (0.647 antibiotics/isolate) (Mann–Whitney U, W = 2449.5, p < 0.01). Analysis of the predominant CA-MRSA group (ST 8 with SCCmec IVa, n = 36), revealed no resistance to clindamycin (p = 0.02448, Χ2 = 5.0602, df = 1) compared to the entire CA-MRSA group (n = 54).

3.4. Virulence Factor Carriage

As shown in Figure 6, most of the VF genes investigated were present in 50–80% of isolates, with higher frequency for MRSA strains in general. Some VFs, i.e., eta and etb, were only found in MSSA strains, whereas others (bbp, cna, sea, sep, tst), were less common (<10%) and not associated with methicillin resistance or sensitivity. clfA, spA, sbi, scpA, and vwb were present in all isolates and are described in Table 5. The carriage of six genes varied significantly based on methicillin resistance, according to Fisher’s exact test: chp (p = 0.004), cna (p = 0.0213), ecb (p = 0.009), pvl (p < 0.0001), sak (p = 0.0387), and splB (p = 0.0403); see Table 5. Whilst the direction of the significance could not be determined, their prevalence was proportionally higher for MRSA than MSSA for all but cna, where the trend was reversed.
We also investigated whether any trends were evident for VF gene carriage based on lineage, excluding those identified as present in all isolates (Table 5). As shown in Figure 7, several genes are conserved across CC and ST for presence or absence as demonstrated by bold red (100% carriage) or bold green (no carriage).
In comparing VF carriage by infection type (Figure 8), four genes varied significantly chp (p = 0.0185), pvl (p < 0.01), sea (p < 0.01), and sep (p < 0.01), described in Table 6. A higher proportion of SSTI isolates carried chp and pvl, whilst sep carriage was highest in blood isolates. sea prevalence was similar for blood and urine isolates, with a much lower carriage in SSTI isolates.
Using Pearson’s correlation, two pairs of genes showed a strong relationship and are associated with lukGH. A strong positive correlation was found between lukGH and splB (0.76), whilst a strong negative correlation was found between lukGH and cna (−0.81), as shown in Figure 9. All other correlations were moderate to low.

4. Discussion

4.1. Sequence Type, Clonal Complex, and SCCmec Distribution

Clonal analysis of S. aureus revealed important lineage information of the genomic makeup of the isolates found in communities of Southeastern Virginia. Although isolates were from a children’s hospital, pediatric trends reflect those of adults in the US, thus providing valuable data on S. aureus presence in this region [79]. CC 8, specifically ST 8, dominated for both MRSA and MSSA, as well as SSTI and blood isolates. Within the small set of urine-associated isolates, two were of CC 8, whereas none were ST 8, which may point to a clonal proclivity for a particular infection setting. A wider variation in ST was evident for the CA-MSSA isolates, which coincides with an expected greater diversity in this group, and perhaps a higher degree of unpredictability.
To further characterize the CA-MRSA isolates, we determined the type of SCCmec, a mobile genetic element that contains the mecA gene affording methicillin resistance [80]. In the CA-MRSA group, the most common SCCmec type was IVa. Of interest, USA300, the predominant CA-MRSA in the US, is ST 8 and contains SCCmec IVa, indicating that most of our CA-MRSA isolates may be USA300 clones. Although at low levels, additional SCCmec types were identified, which supports a varied presence in communities of Southeastern Virginia. USA300 has a well-documented history of infection across the US [81,82,83,84]. Given its success as a pathogen, having this lineage dominate our CA-MRSA pool is not surprising.
To investigate whether lineage correlates with infection, we cross-referenced the clonal data with infection type (SSTI, blood, and urine) revealing a significant difference for both CC and ST, thus identifying a connection between lineage and a particular disease state. Some CCs are reported to be highly associated with virulence models, such as infections of the blood or bone, indicating tropism for particular areas of the body [85,86]. Our analyses support these findings, providing additional sequence-type evidence to validate the usefulness of identifying lineage data.

4.2. Antibiograms

Community-associated S. aureus infections are commonly treated with dicloxacillin or cephalexin; however, patients allergic to penicillin may be prescribed erythromycin or similar antibiotics [87]. When MRSA is suspected or confirmed, sulfonamides or oxazolidinones are typically administered [87]. Serious infections are treated by considering documented sensitivities in the case of MRSA, or oxacillin for MSSA. Patients with penicillin allergy may be treated with clindamycin or vancomycin, but the former is not recommended when MRSA is suspected or confirmed [87]. Our data broadly support these guidelines. MRSA are known for frequent erythromycin resistance, but our finding of 40% erythromycin resistance in MSSA is still concerning and indicative of a potential change in the antibiotic resistance landscape [10]. The lack of rifampin or vancomycin resistance in our sample pool indicates that these antibiotics may remain viable treatment options for the near term. Clindamycin and erythromycin resistance were highest in blood isolates, indicating that this infection type may be at the highest risk of limited treatment options; this, coupled with the serious outcomes associated with S. aureus bacteremia, is of major concern. Whilst SSTI isolates exhibited a relatively low occurrence of clindamycin resistance, this trend may increase due to S. aureus’ proclivity to developing resistance to antimicrobials. This is particularly worrisome for treating patients with drug allergies [11,14,15,87]. Interestingly, the predominant CA-MRSA lineage, ST 8 SCCmec IVa, exhibited no resistance to clindamycin. As USA300 isolates are resistant to fewer classes of antibiotics than their cohorts, this further supports that these isolates may be USA300 clones [83].

4.3. Virulence Factor Carriage

Five of the genes of interest were found in all clinical isolates screened: clfA, scpA, sbi, spA, and vwb. Whilst four of the five genes produce adhesins, all are involved in immune evasion, thus promoting S. aureus survival within the host, particularly where these properties intercept through the formation of biofilm [18]. As such, global carriage of these genes highlights their significance to S. aureus pathogenicity in multiple disease settings.
Six VFs were found to vary significantly with methicillin resistance: chp, cna, ecb, pvl, sak, and splB. Of these, only cna was more common in MSSA isolates than MRSA isolates. This falls in line with the literature, as MRSA are typically considered to be more virulent than MSSA. Again, these VFs are implicated in immune evasion, targeting the complement system or effector cells directly. As chp and sak belong to the same phage-encoded pathogenicity island, this suggests that their carriage would occur together [78]. pvl presence is implicated in severe disease and is associated with USA300. A high percentage of CA-MRSA in our sample pool were pvl+ (70%), indicating a high presence of this VF in MRSA isolates associated with communities of Southeastern Virginia.
Four VFs varied significantly with infection type: chp, pvl, sea, and sep (Figure 7 and Table 6). SSTI isolates were found to carry chp and splB more frequently, but were less likely to carry sea. Only sep was found most frequently in blood isolates, which supports a study by Calderwood, et al., demonstrating a significant link between sep carriage and the development of bacteremia [88]. Interestingly, the carriage of chp and sea was similar between blood and urine isolates, suggesting that their carriage may support invasive infections.
Several other VF genes were well represented across isolates and infection type, indicating their utility in S. aureus biology and corresponding pathogenicity. These included adhesins, toxins, proteases, and inhibitors, implicating a measurable benefit for their presence. A few of the VF genes were rare, namely the toxin genes eta, etb, and tst. Of interest, these were found in CA-MSSA only, and were predominantly of SSTI (no blood; one urine had etb). Some rare VFs were associated with a specific CC (e.g., eta/etb and CC 121), indicating that VF gene carriage may be predicted based on lineage, highlighting the benefit of isolate-specific data. CC 121 was uncommon in our sample pool (3%); however, this clone is globally disseminated and associated with the exfoliative toxins, with documented increasing resistance to vancomycin [89,90]. Although none of the isolates included in this study demonstrated resistance to vancomycin, the probability of reduced susceptibility to available antibiotics is likely to occur overtime, supporting the dire need to develop novel treatment strategies.

5. Conclusions

In this study, we determined the genetic variability of 122 S. aureus clinical isolates from patients of a pediatric hospital serving Southeastern Virginia. As pediatric trends reflect those of adults in the US, this study provides valuable data on S. aureus presence in this region [79]. Most of the isolates were associated with SSTI with significantly less from systemic blood and urinary tract infections, mirroring the dominant role of S. aureus as the largest single cause of SSTI worldwide. The most common lineage was CC 8, of which most were ST 8. In combination with SCCmec IVa dominating for CA-MRSA isolates, this lineage aligns with that of USA300. Additional STs identified for the CA-MSSA group indicates that CA-MSSA are likely to be less predictable than CA-MRSA due to an increased variability in lineage. Antibiogram data demonstrated a high prevalence of erythromycin resistance for isolates from both SSTI and blood infections, with blood isolates exhibiting the highest clindamycin resistance of any group analyzed. The carriage of select VF-associated genes varied significantly based on methicillin resistance and/or infection type; however, five genes were present in all isolates. The overwhelming commonality linking these genes is their association with immune evasion, in particular targeting the complement system and phagocytes. As S. aureus is often referred to as a master of immune evasion, these conserved genes, as well as those with high carriage, present an opportunity for further investigation. Understanding the level of VF gene carriage and pathogenic potential coupled with readily accessible clinical characteristics may support the development of better directed antistaphylococcal strategies.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pathogens13010025/s1: gene carriage, antibiograms, CC group counts and ST group counts.

Author Contributions

Conceptualization, J.A.S. and K.D.C.; methodology, J.A.S. and K.D.C.; validation, K.D.C. and J.A.S.; formal analysis, J.A.S., K.D.C. and M.D.P.; investigation, J.A.S. and K.D.C.; resources, J.A.S. and S.Q.; data curation, K.D.C. and S.Q.; writing—original draft preparation, K.D.C. and J.A.S.; writing—review and editing, K.D.C. and J.A.S.; visualization, J.A.S. and M.D.P.; supervision, J.A.S. and S.Q.; project administration, J.A.S.; funding acquisition, J.A.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by grant funding from Virginia’s Commonwealth Health Research Board, grant number 274-04-22, www.CHRB.org to J.A.S.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available in Supplementary Materials.

Acknowledgments

We would like to acknowledge the support of the EVMS Molecular Core Facility.

Conflicts of Interest

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Taylor, T.A.; Unakal, C.G. Staphylococcus aureus Infection; StatPearls Publishing: Treasure Island, FL, USA, 2023.
  2. Cheung, G.Y.C.; Bae, J.S.; Otto, M. Pathogenicity and virulence of Staphylococcus aureus. Virulence 2021, 12, 547–569. [Google Scholar] [CrossRef]
  3. Grigg, C.; Palms, D.; Stone, N.D.; Gualandi, N.; Bamberg, W.; Dumyati, G.; Harrison, L.H.; Lynfield, R.; Nadle, J.; Petit, S.; et al. Burden of Invasive Methicillin-Resistant Staphylococcus aureus Infections in Nursing Home Residents. J. Am. Geriatr. Soc. 2018, 66, 1581–1586. [Google Scholar] [CrossRef]
  4. Jones, M.; Jernigan, J.A.; Evans, M.E.; Roselle, G.A.; Hatfield, K.M.; Samore, M.H. Vital Signs: Trends in Staphylococcus aureus Infections in Veterans Affairs Medical Centers–United States, 2005–2017. MMWR Morb. Mortal. Wkly. Rep. 2019, 68, 220–224. [Google Scholar] [CrossRef]
  5. Koeck, M.; Como-Sabetti, K.; Boxrud, D.; Dobbins, G.; Glennen, A.; Anacker, M.; Jawahir, S.; See, I.; Lynfield, R. Burdens of Invasive Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Disease, Minnesota, USA. Emerg. Infect. Dis. 2019, 25, 171–174. [Google Scholar] [CrossRef]
  6. Jackson, K.A.; Gokhale, R.H.; Nadle, J.; Ray, S.M.; Dumyati, G.; Schaffner, W.; Ham, D.C.; Magill, S.S.; Lynfield, R.; See, I. Public Health Importance of Invasive Methicillin-sensitive Staphylococcus aureus Infections: Surveillance in 8 US Counties, 2016. Clin. Infect Dis. 2020, 70, 1021–1028. [Google Scholar] [CrossRef]
  7. Hasman, H.; Moodley, A.; Guardabassi, L.; Stegger, M.; Skov, R.L.; Aarestrup, F.M. Spa type distribution in Staphylococcus aureus originating from pigs, cattle and poultry. Vet. Microbiol. 2010, 141, 326–331. [Google Scholar] [CrossRef]
  8. Thapaliya, D.; Kadariya, J.; Capuano, M.; Rush, H.; Yee, C.; Oet, M.; Lohani, S.; Smith, T.C. Prevalence and Molecular Characterization of Staphylococcus aureus and Methicillin-resistant S. aureus on Children’s Playgrounds. Pediatr. Infect. Dis. J. 2019, 38, e43–e47. [Google Scholar] [CrossRef]
  9. Turner, N.A.; Sharma-Kuinkel, B.K.; Maskarinec, S.A.; Eichenberger, E.M.; Shah, P.P.; Carugati, M.; Holland, T.L.; Fowler, V.G., Jr. Methicillin-resistant Staphylococcus aureus: An overview of basic and clinical research. Nat. Rev. Microbiol. 2019, 17, 203–218. [Google Scholar] [CrossRef]
  10. Diekema, D.J.; Pfaller, M.A.; Shortridge, D.; Zervos, M.; Jones, R.N. Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program. Open Forum Infect. Dis. 2019, 6, S47–S53. [Google Scholar] [CrossRef]
  11. Siberry, G.K.; Tekle, T.; Carroll, K.; Dick, J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin. Infect. Dis. 2003, 37, 1257–1260. [Google Scholar] [CrossRef]
  12. Walters, M.S.; Eggers, P.; Albrecht, V.; Travis, T.; Lonsway, D.; Hovan, G.; Taylor, D.; Rasheed, K.; Limbago, B.; Kallen, A. Vancomycin-Resistant Staphylococcus aureus–Delaware, 2015. MMWR Morb. Mortal. Wkly. Rep. 2015, 64, 1056. [Google Scholar] [CrossRef]
  13. Walters, M.S.; Rasheed, K.; Albrecht, V.; McAllister, S.; Limbago, B.; Kallen, A. Investigation and Control of Vancomycin-Resistant Staphylococcus aureus (VRSA): 2015 Update; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2015.
  14. Ghosh, S.; Banerjee, M. Methicillin resistance & inducible clindamycin resistance in Staphylococcus aureus. Indian J. Med. Res. 2016, 143, 362–364. [Google Scholar] [CrossRef]
  15. Jarajreh, D.; Aqel, A.; Alzoubi, H.; Al-Zereini, W. Prevalence of inducible clindamycin resistance in methicillin-resistant Staphylococcus aureus: The first study in Jordan. J. Infect. Dev. Ctries. 2017, 11, 350–354. [Google Scholar] [CrossRef]
  16. Rha, B.; See, I.; Dunham, L.; Kutty, P.K.; Moccia, L.; Apata, I.W.; Ahern, J.; Jung, S.; Li, R.; Nadle, J.; et al. Vital Signs: Health Disparities in Hemodialysis-Associated Staphylococcus aureus Bloodstream Infections - United States, 2017–2020. MMWR Morb. Mortal. Wkly. Rep. 2023, 72, 153–159. [Google Scholar] [CrossRef]
  17. Ricklin, D.; Tzekou, A.; Garcia, B.L.; Hammel, M.; McWhorter, W.J.; Sfyroera, G.; Wu, Y.Q.; Holers, V.M.; Herbert, A.P.; Barlow, P.N.; et al. A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J. Immunol. 2009, 183, 2565–2574. [Google Scholar] [CrossRef]
  18. Paharik, A.E.; Horswill, A.R. The Staphylococcal Biofilm: Adhesins, Regulation, and Host Response. Microbiol. Spectr. 2016, 4, 529–566. [Google Scholar] [CrossRef]
  19. Chavakis, T.; Wiechmann, K.; Preissner, K.T.; Herrmann, M. Staphylococcus aureus interactions with the endothelium: The role of bacterial “secretable expanded repertoire adhesive molecules” (SERAM) in disturbing host defense systems. Thromb. Haemost. 2005, 94, 278–285. [Google Scholar] [CrossRef]
  20. Oliveira, D.; Borges, A.; Simoes, M. Staphylococcus aureus Toxins and Their Molecular Activity in Infectious Diseases. Toxins 2018, 10, 252. [Google Scholar] [CrossRef]
  21. Rooijakkers, S.H.; Ruyken, M.; Roos, A.; Daha, M.R.; Presanis, J.S.; Sim, R.B.; van Wamel, W.J.; van Kessel, K.P.; van Strijp, J.A. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 2005, 6, 920–927. [Google Scholar] [CrossRef]
  22. de Haas, C.J.; Veldkamp, K.E.; Peschel, A.; Weerkamp, F.; Van Wamel, W.J.; Heezius, E.C.; Poppelier, M.J.; Van Kessel, K.P.; van Strijp, J.A. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J. Exp. Med. 2004, 199, 687–695. [Google Scholar] [CrossRef]
  23. Postma, B.; Poppelier, M.J.; van Galen, J.C.; Prossnitz, E.R.; van Strijp, J.A.; de Haas, C.J.; van Kessel, K.P. Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor. J. Immunol. 2004, 172, 6994–7001. [Google Scholar] [CrossRef] [PubMed]
  24. Loffler, B.; Hussain, M.; Grundmeier, M.; Bruck, M.; Holzinger, D.; Varga, G.; Roth, J.; Kahl, B.C.; Proctor, R.A.; Peters, G. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog. 2010, 6, e1000715. [Google Scholar] [CrossRef] [PubMed]
  25. Hair, P.S.; Echague, C.G.; Sholl, A.M.; Watkins, J.A.; Geoghegan, J.A.; Foster, T.J.; Cunnion, K.M. Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. Infect. Immun. 2010, 78, 1717–1727. [Google Scholar] [CrossRef] [PubMed]
  26. Sharp, J.A.; Echague, C.G.; Hair, P.S.; Ward, M.D.; Nyalwidhe, J.O.; Geoghegan, J.A.; Foster, T.J.; Cunnion, K.M. Staphylococcus aureus surface protein SdrE binds complement regulator factor H as an immune evasion tactic. PLoS ONE 2012, 7, e38407. [Google Scholar] [CrossRef] [PubMed]
  27. Smith, E.J.; Visai, L.; Kerrigan, S.W.; Speziale, P.; Foster, T.J. The Sbi protein is a multifunctional immune evasion factor of Staphylococcus aureus. Infect. Immun. 2011, 79, 3801–3809. [Google Scholar] [CrossRef] [PubMed]
  28. Ladhani, S. Understanding the mechanism of action of the exfoliative toxins of Staphylococcus aureus. FEMS Immunol. Med. Microbiol. 2003, 39, 181–189. [Google Scholar] [CrossRef]
  29. Kulhankova, K.; King, J.; Salgado-Pabon, W. Staphylococcal toxic shock syndrome: Superantigen-mediated enhancement of endotoxin shock and adaptive immune suppression. Immunol. Res. 2014, 59, 182–187. [Google Scholar] [CrossRef]
  30. Jiang, B.; Wang, Y.; Feng, Z.; Xu, L.; Tan, L.; Zhao, S.; Gong, Y.; Zhang, C.; Luo, X.; Li, S.; et al. Panton-Valentine leucocidin (PVL) as a potential indicator for prevalence, duration, and severity of Staphylococcus aureus osteomyelitis. Front. Microbiol. 2017, 8, 2355. [Google Scholar] [CrossRef]
  31. Huang, J.; Zhang, T.; Zou, X.; Wu, S.; Zhu, J. Panton-Valentine leucocidin carrying Staphylococcus aureus causing necrotizing pneumonia inactivates the JAK/STAT signaling pathway and increases the expression of inflammatory cytokines. Infect. Genet. Evol. 2020, 86, 104582. [Google Scholar] [CrossRef]
  32. Castellazzi, M.L.; Bosis, S.; Borzani, I.; Tagliabue, C.; Pinzani, R.; Marchisio, P.; di Pietro, G.M. Panton-Valentine leukocidin Staphylococcus aureus severe infection in an infant: A case report and a review of the literature. Ital. J. Pediatr. 2021, 47, 158. [Google Scholar] [CrossRef]
  33. Wurster, J.I.; Bispo, P.J.M.; Van Tyne, D.; Cadorette, J.J.; Boody, R.; Gilmore, M.S. Staphylococcus aureus from ocular and otolaryngology infections are frequently resistant to clinically important antibiotics and are associated with lineages of community and hospital origins. PLoS ONE 2018, 13, e0208518. [Google Scholar] [CrossRef] [PubMed]
  34. Sharma, H.; Smith, D.; Turner, C.E.; Game, L.; Pichon, B.; Hope, R.; Hill, R.; Kearns, A.; Sriskandan, S. Clinical and molecular epidemiology of staphylococcal toxic shock syndrome in the United Kingdom. Emerg. Infect. Dis. 2018, 24, 258–266. [Google Scholar] [CrossRef]
  35. Ganesh, V.K.; Rivera, J.J.; Smeds, E.; Ko, Y.P.; Bowden, M.G.; Wann, E.R.; Gurusiddappa, S.; Fitzgerald, J.R.; Hook, M. A structural model of the Staphylococcus aureus ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics. PLoS Pathog. 2008, 4, e1000226. [Google Scholar] [CrossRef] [PubMed]
  36. Kang, M.; Ko, Y.P.; Liang, X.; Ross, C.L.; Liu, Q.; Murray, B.E.; Hook, M. Collagen-binding microbial surface components recognizing adhesive matrix molecule (MSCRAMM) of Gram-positive bacteria inhibit complement activation via the classical pathway. J. Biol. Chem. 2013, 288, 20520–20531. [Google Scholar] [CrossRef] [PubMed]
  37. Eisenbeis, J.; Saffarzadeh, M.; Peisker, H.; Jung, P.; Thewes, N.; Preissner, K.T.; Herrmann, M.; Molle, V.; Geisbrecht, B.V.; Jacobs, K.; et al. The Staphylococcus aureus extracellular adherence protein Eap is a DNA binding protein capable of blocking neutrophil extracellular trap formation. Front. Cell. Infect. Microbiol. 2018, 8, 235. [Google Scholar] [CrossRef]
  38. Hammel, M.; Sfyroera, G.; Pyrpassopoulos, S.; Ricklin, D.; Ramyar, K.X.; Pop, M.; Jin, Z.; Lambris, J.D.; Geisbrecht, B.V. Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureus. J. Biol. Chem. 2007, 282, 30051–30061. [Google Scholar] [CrossRef]
  39. Amdahl, H.; Haapasalo, K.; Tan, L.; Meri, T.; Kuusela, P.I.; van Strijp, J.A.; Rooijakkers, S.; Jokiranta, T.S. Staphylococcal protein Ecb impairs complement receptor-1 mediated recognition of opsonized bacteria. PLoS ONE 2017, 12, e0172675. [Google Scholar] [CrossRef]
  40. Posner, M.G.; Upadhyay, A.; Abubaker, A.A.; Fortunato, T.M.; Vara, D.; Canobbio, I.; Bagby, S.; Pula, G. Extracellular fibrinogen-binding protein (Efb) from Staphylococcus aureus inhibits the formation of platelet-leukocyte complexes. J. Biol. Chem. 2016, 291, 2764–2776. [Google Scholar] [CrossRef]
  41. Koch, T.K.; Reuter, M.; Barthel, D.; Bohm, S.; van den Elsen, J.; Kraiczy, P.; Zipfel, P.F.; Skerka, C. Staphylococcus aureus proteins Sbi and Efb recruit human plasmin to degrade complement C3 and C3b. PLoS ONE 2012, 7, e47638. [Google Scholar] [CrossRef]
  42. Geraci, J.; Neubauer, S.; Pollath, C.; Hansen, U.; Rizzo, F.; Krafft, C.; Westermann, M.; Hussain, M.; Peters, G.; Pletz, M.W.; et al. The Staphylococcus aureus extracellular matrix protein (Emp) has a fibrous structure and binds to different extracellular matrices. Sci. Rep. 2017, 7, 13665. [Google Scholar] [CrossRef]
  43. Berube, B.J.; Bubeck Wardenburg, J. Staphylococcus aureus alpha-toxin: Nearly a century of intrigue. Toxins 2013, 5, 1140–1166. [Google Scholar] [CrossRef] [PubMed]
  44. Spaan, A.N.; van Strijp, J.A.G.; Torres, V.J. Leukocidins: Staphylococcal bi-component pore-forming toxins find their receptors. Nat. Rev. Microbiol. 2017, 15, 435–447. [Google Scholar] [CrossRef] [PubMed]
  45. Rooijakkers, S.H.; van Wamel, W.J.; Ruyken, M.; van Kessel, K.P.; van Strijp, J.A. Anti-opsonic properties of staphylokinase. Microbes Infect. 2005, 7, 476–484. [Google Scholar] [CrossRef] [PubMed]
  46. Smith, E.J.; Corrigan, R.M.; van der Sluis, T.; Grundling, A.; Speziale, P.; Geoghegan, J.A.; Foster, T.J. The immune evasion protein Sbi of Staphylococcus aureus occurs both extracellularly and anchored to the cell envelope by binding lipoteichoic acid. Mol. Microbiol. 2012, 83, 789–804. [Google Scholar] [CrossRef]
  47. Jusko, M.; Potempa, J.; Kantyka, T.; Bielecka, E.; Miller, H.K.; Kalinska, M.; Dubin, G.; Garred, P.; Shaw, L.N.; Blom, A.M. Staphylococcal proteases aid in evasion of the human complement system. J. Innate Immun. 2014, 6, 31–46. [Google Scholar] [CrossRef]
  48. Feuillie, C.; Formosa-Dague, C.; Hays, L.M.; Vervaeck, O.; Derclaye, S.; Brennan, M.P.; Foster, T.J.; Geoghegan, J.A.; Dufrene, Y.F. Molecular interactions and inhibition of the staphylococcal biofilm-forming protein SdrC. Proc. Natl. Acad. Sci. USA 2017, 114, 3738–3743. [Google Scholar] [CrossRef]
  49. Askarian, F.; Ajayi, C.; Hanssen, A.M.; van Sorge, N.M.; Pettersen, I.; Diep, D.B.; Sollid, J.U.; Johannessen, M. The interaction between Staphylococcus aureus SdrD and desmoglein 1 is important for adhesion to host cells. Sci. Rep. 2016, 6, 22134. [Google Scholar] [CrossRef]
  50. Cavallin, A.; Arozenius, H.; Kristensson, K.; Antonsson, P.; Otzen, D.E.; Bjork, P.; Forsberg, G. The spectral and thermodynamic properties of staphylococcal enterotoxin A, E, and variants suggest that structural modifications are important to control their function. J. Biol. Chem. 2000, 275, 1665–1672. [Google Scholar] [CrossRef]
  51. Omoe, K.; Hu, D.L.; Ono, H.K.; Shimizu, S.; Takahashi-Omoe, H.; Nakane, A.; Uchiyama, T.; Shinagawa, K.; Imanishi, K. Emetic potentials of newly identified staphylococcal enterotoxin-like toxins. Infect. Immun. 2013, 81, 3627–3631. [Google Scholar] [CrossRef]
  52. Falugi, F.; Kim, H.K.; Missiakas, D.M.; Schneewind, O. Role of protein A in the evasion of host adaptive immune responses by Staphylococcus aureus. mBio 2013, 4, e00575-13. [Google Scholar] [CrossRef]
  53. Dasari, P.; Nordengrun, M.; Vilhena, C.; Steil, L.; Abdurrahman, G.; Surmann, K.; Dhople, V.; Lahrberg, J.; Bachert, C.; Skerka, C.; et al. The protease SplB of Staphylococcus aureus targets host complement components and inhibits complement-mediated bacterial opsonophagocytosis. J. Bacteriol. 2022, 204, e0018421. [Google Scholar] [CrossRef]
  54. de Jong, N.W.M.; Ramyar, K.X.; Guerra, F.E.; Nijland, R.; Fevre, C.; Voyich, J.M.; McCarthy, A.J.; Garcia, B.L.; van Kessel, K.P.M.; van Strijp, J.A.G.; et al. Immune evasion by a staphylococcal inhibitor of myeloperoxidase. Proc. Natl. Acad. Sci. USA 2017, 114, 9439–9444. [Google Scholar] [CrossRef]
  55. Bestebroer, J.; Aerts, P.C.; Rooijakkers, S.H.; Pandey, M.K.; Kohl, J.; van Strijp, J.A.; de Haas, C.J. Functional basis for complement evasion by staphylococcal superantigen-like 7. Cell. Microbiol. 2010, 12, 1506–1516. [Google Scholar] [CrossRef]
  56. Thomer, L.; Schneewind, O.; Missiakas, D. Multiple ligands of von Willebrand factor-binding protein (vWbp) promote Staphylococcus aureus clot formation in human plasma. J. Biol. Chem. 2013, 288, 28283–28292. [Google Scholar] [CrossRef]
  57. Seemann, T. Prokka: Rapid prokaryotic genome annotation. Bioinformatics 2014, 30, 2068–2069. [Google Scholar] [CrossRef]
  58. Jolley, K.A.; Bray, J.E.; Maiden, M.C.J. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res. 2018, 3, 124. [Google Scholar] [CrossRef]
  59. Enright, M.C.; Day, N.P.; Davies, C.E.; Peacock, S.J.; Spratt, B.G. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 2000, 38, 1008–1015. [Google Scholar] [CrossRef]
  60. Zhang, K.; McClure, J.A.; Elsayed, S.; Louie, T.; Conly, J.M. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 2005, 43, 5026–5033. [Google Scholar] [CrossRef]
  61. Zhang, K.; McClure, J.A.; Conly, J.M. Enhanced multiplex PCR assay for typing of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. Mol. Cell. Probes 2012, 26, 218–221. [Google Scholar] [CrossRef]
  62. Tristan, A.; Ying, L.; Bes, M.; Etienne, J.; Vandenesch, F.; Lina, G. Use of multiplex PCR to identify Staphylococcus aureus adhesins involved in human hematogenous infections. J. Clin. Microbiol. 2003, 41, 4465–4467. [Google Scholar] [CrossRef] [PubMed]
  63. Cruz, A.R.; van Strijp, J.A.G.; Bagnoli, F.; Manetti, A.G.O. Virulence gene expression of Staphylococcus aureus in human skin. Front. Microbiol. 2021, 12, 692023. [Google Scholar] [CrossRef]
  64. Kato, F.; Kadomoto, N.; Iwamoto, Y.; Bunai, K.; Komatsuzawa, H.; Sugai, M. Regulatory mechanism for exfoliative toxin production in Staphylococcus aureus. Infect. Immun. 2011, 79, 1660–1670. [Google Scholar] [CrossRef]
  65. Karmakar, A.; Jana, D.; Dutta, K.; Dua, P.; Ghosh, C. Prevalence of Panton-Valentine leukocidin gene among community acquired Staphylococcus aureus: A real-time PCR study. J. Pathog. 2018, 2018, 4518541. [Google Scholar] [CrossRef]
  66. Oogai, Y.; Matsuo, M.; Hashimoto, M.; Kato, F.; Sugai, M.; Komatsuzawa, H. Expression of virulence factors by Staphylococcus aureus grown in serum. Appl. Environ. Microbiol. 2011, 77, 8097–8105. [Google Scholar] [CrossRef]
  67. Sabat, A.; Melles, D.C.; Martirosian, G.; Grundmann, H.; van Belkum, A.; Hryniewicz, W. Distribution of the serine-aspartate repeat protein-encoding sdr genes among nasal-carriage and invasive Staphylococcus aureus strains. J. Clin. Microbiol. 2006, 44, 1135–1138. [Google Scholar] [CrossRef]
  68. Nielsen, L.N.; Roggenbuck, M.; Haaber, J.; Ifrah, D.; Ingmer, H. Diverse modulation of spa transcription by cell wall active antibiotics in Staphylococcus aureus. BMC Res. Notes 2012, 5, 457. [Google Scholar] [CrossRef]
  69. R Core Team. R: A Language and Environment for Statistical Computing, Version R-4.2.3; R Foundation for Statistical Computing: Vienna, Austria, 2021. [Google Scholar]
  70. Wickham, H.; Bryan, J. readxl: Read Excel Files. 2023. Available online: https://github.com/tidyverse/readxl (accessed on 23 October 2023).
  71. Wickham, H.; François, R.; Henry, L.; Müller, K.; Vaughan, D. dplyr: A Grammar of Data Manipulation. 2023. Available online: https://github.com/tidyverse/dplyr (accessed on 23 October 2023).
  72. Wickham, H. ggplot2: Elegant Graphics for Data Analysis; Springer: New York, NY, USA, 2016. [Google Scholar]
  73. Kassambara, A. ggcorrplot: Visualization of a Correlation Matrix Using ‘ggplot2’; Springer: New York, NY, USA, 2023. [Google Scholar]
  74. Mehta, C.R.; Patel, N.R. A hybrid algorithm for Fisher’s exact test in unordered RXC contingency tables. Commun. Stat. Theory Methods 1986, 15, 387–403. [Google Scholar] [CrossRef]
  75. O’Brien, L.; Kerrigan, S.W.; Kaw, G.; Hogan, M.; Penades, J.; Litt, D.; Fitzgerald, D.J.; Foster, T.J.; Cox, D. Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: Roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. Mol. Microbiol. 2002, 44, 1033–1044. [Google Scholar] [CrossRef] [PubMed]
  76. Ghasemian, A.; Najar Peerayeh, S.; Bakhshi, B.; Mirzaee, M. The microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) genes among clinical isolates of Staphylococcus aureus from hospitalized children. Iran. J. Pathol. 2015, 10, 258–264. [Google Scholar] [PubMed]
  77. Pinchuk, I.V.; Beswick, E.J.; Reyes, V.E. Staphylococcal enterotoxins. Toxins 2010, 2, 2177–2197. [Google Scholar] [CrossRef] [PubMed]
  78. van Wamel, W.J.; Rooijakkers, S.H.; Ruyken, M.; van Kessel, K.P.; van Strijp, J.A. The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of Staphylococcus aureus are located on beta-hemolysin-converting bacteriophages. J. Bacteriol. 2006, 188, 1310–1315. [Google Scholar] [CrossRef]
  79. Sutter, D.E.; Milburn, E.; Chukwuma, U.; Dzialowy, N.; Maranich, A.M.; Hospenthal, D.R. Changing Susceptibility of Staphylococcus aureus in a US Pediatric Population. Pediatrics 2016, 137, e20153099. [Google Scholar] [CrossRef]
  80. Uehara, Y. Current Status of Staphylococcal Cassette Chromosome mec (SCCmec). Antibiotics 2022, 11, 86. [Google Scholar] [CrossRef]
  81. Tenover, F.C.; Goering, R.V. Methicillin-resistant Staphylococcus aureus strain USA300: Origin and epidemiology. J. Antimicrob. Chemother. 2009, 64, 441–446. [Google Scholar] [CrossRef]
  82. Diekema, D.J.; Richter, S.S.; Heilmann, K.P.; Dohrn, C.L.; Riahi, F.; Tendolkar, S.; McDanel, J.S.; Doern, G.V. Continued emergence of USA300 methicillin-resistant Staphylococcus aureus in the United States: Results from a nationwide surveillance study. Infect. Control Hosp. Epidemiol. 2014, 35, 285–292. [Google Scholar] [CrossRef]
  83. Sansom, S.E.; Benedict, E.; Thiede, S.N.; Hota, B.; Aroutcheva, A.; Payne, D.; Zawitz, C.; Snitkin, E.S.; Green, S.J.; Weinstein, R.A.; et al. Genomic update of phenotypic prediction rule for methicillin-resistant Staphylococcus aureus (MRSA) USA300 discloses jail transmission networks with increased resistance. Microbiol. Spectr. 2021, 9, e0037621. [Google Scholar] [CrossRef]
  84. Thiede, S.N.; Snitkin, E.S.; Trick, W.; Payne, D.; Aroutcheva, A.; Weinstein, R.A.; Popovich, K.J. Genomic epidemiology suggests community origins of healthcare-associated USA300 methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 2022, 226, 157–166. [Google Scholar] [CrossRef]
  85. Valour, F.; Tasse, J.; Trouillet-Assant, S.; Rasigade, J.P.; Lamy, B.; Chanard, E.; Verhoeven, P.; Decousser, J.W.; Marchandin, H.; Bes, M.; et al. Methicillin-susceptible Staphylococcus aureus clonal complex 398: High prevalence and geographical heterogeneity in bone and joint infection and nasal carriage. Clin. Microbiol. Infect. 2014, 20, O772–O775. [Google Scholar] [CrossRef]
  86. Sharma-Kuinkel, B.K.; Mongodin, E.F.; Myers, J.R.; Vore, K.L.; Canfield, G.S.; Fraser, C.M.; Rude, T.H.; Fowler, V.G., Jr.; Gill, S.R. Potential influence of Staphylococcus aureus clonal complex 30 genotype and transcriptome on hematogenous infections. Open Forum Infect. Dis. 2015, 2, ofv093. [Google Scholar] [CrossRef] [PubMed]
  87. Bush, L.M.; Vazquez-Pertejo, M.T. Staphylococcal Infections. Merck Manual Professional Version. 2023. Available online: https://www.merckmanuals.com/professional/infectious-diseases/gram-positive-cocci/staphylococcal-infections (accessed on 25 October 2023).
  88. Calderwood, M.S.; Desjardins, C.A.; Sakoulas, G.; Nicol, R.; Dubois, A.; Delaney, M.L.; Kleinman, K.; Cosimi, L.A.; Feldgarden, M.; Onderdonk, A.B.; et al. Staphylococcal enterotoxin P predicts bacteremia in hospitalized patients colonized with methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 2014, 209, 571–577. [Google Scholar] [CrossRef] [PubMed]
  89. Kurt, K.; Rasigade, J.P.; Laurent, F.; Goering, R.V.; Zemlickova, H.; Machova, I.; Struelens, M.J.; Zautner, A.E.; Holtfreter, S.; Broker, B.; et al. Subpopulations of Staphylococcus aureus clonal complex 121 are associated with distinct clinical entities. PLoS ONE 2013, 8, e58155. [Google Scholar] [CrossRef]
  90. Shen, P.; Zhou, K.; Wang, Y.; Song, J.; Liu, Y.; Zhou, Y.; Xiao, Y. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China. J. Antimicrob. Chemother. 2019, 74, 2537–2543. [Google Scholar] [CrossRef]
Figure 1. Isolate pool characterization of community association S. aureus. Isolate pool characterization of community associated S. aureus. MRSA and MSSA members are subdivided by infection type.
Figure 1. Isolate pool characterization of community association S. aureus. Isolate pool characterization of community associated S. aureus. MRSA and MSSA members are subdivided by infection type.
Pathogens 13 00025 g001
Figure 2. Isolate lineage analyses for MRSA vs. MSSA. Distribution of CC (A) and ST (B). Analysis of the most common CC (C) and corresponding ST (D). CCs and STs that contain ≥ 3 are shown. Groups not meeting this requirement were placed in “Other”. N/A represent members with recognized STs and no defined CC.
Figure 2. Isolate lineage analyses for MRSA vs. MSSA. Distribution of CC (A) and ST (B). Analysis of the most common CC (C) and corresponding ST (D). CCs and STs that contain ≥ 3 are shown. Groups not meeting this requirement were placed in “Other”. N/A represent members with recognized STs and no defined CC.
Pathogens 13 00025 g002
Figure 3. Isolate lineage analyses based on infection type. Distribution of CC (A) and ST (B). Represented CCs contain ≥ 4; represented STs contain ≥ 3. Groups not meeting this requirement were placed in “Other”. N/A represent members with recognized STs and no defined CC. Analysis of the four most common CC (C) and corresponding ST (D).
Figure 3. Isolate lineage analyses based on infection type. Distribution of CC (A) and ST (B). Represented CCs contain ≥ 4; represented STs contain ≥ 3. Groups not meeting this requirement were placed in “Other”. N/A represent members with recognized STs and no defined CC. Analysis of the four most common CC (C) and corresponding ST (D).
Pathogens 13 00025 g003
Figure 4. SCCmec distribution for MRSA.
Figure 4. SCCmec distribution for MRSA.
Pathogens 13 00025 g004
Figure 5. S. aureus antibiotic resistance. Antibiogram data for (A) MRSA vs. MSSA, (B) infection type. * p < 0.01. The following resistances are not depicted: rifampin (0%), vancomycin (0%), penicillin (99.2%), oxacillin (0% for MSSA, 100% for MRSA).
Figure 5. S. aureus antibiotic resistance. Antibiogram data for (A) MRSA vs. MSSA, (B) infection type. * p < 0.01. The following resistances are not depicted: rifampin (0%), vancomycin (0%), penicillin (99.2%), oxacillin (0% for MSSA, 100% for MRSA).
Pathogens 13 00025 g005
Figure 6. VF gene carriage based on methicillin resistance/sensitivity. For all isolates, MRSA, n = 52 (+2 for genes listed in Table 2) and MSSA groups (n = 68). *** p < 0.0001; ** p < 0.001, * p < 0.05.
Figure 6. VF gene carriage based on methicillin resistance/sensitivity. For all isolates, MRSA, n = 52 (+2 for genes listed in Table 2) and MSSA groups (n = 68). *** p < 0.0001; ** p < 0.001, * p < 0.05.
Pathogens 13 00025 g006
Figure 7. Heatmap of VF gene carriage based on lineage: (A) for CC containing at least 4 isolates; (B) for ST containing at least 3 isolates.
Figure 7. Heatmap of VF gene carriage based on lineage: (A) for CC containing at least 4 isolates; (B) for ST containing at least 3 isolates.
Pathogens 13 00025 g007
Figure 8. Virulence factor carriage by infection type. * p < 0.02.
Figure 8. Virulence factor carriage by infection type. * p < 0.02.
Pathogens 13 00025 g008
Figure 9. Correlation plot of the Pearson correlation coefficient for select VFs. n = 120 (+2 for genes listed in Table 3).
Figure 9. Correlation plot of the Pearson correlation coefficient for select VFs. n = 120 (+2 for genes listed in Table 3).
Pathogens 13 00025 g009
Table 1. Virulence factors of interest.
Table 1. Virulence factors of interest.
GeneVFType 1Group 2Immune-EvasiveRef.
bbpBone Sialoprotein Binding ProteinCWMSCRAMMYes[18]
clfAClumping Factor ACWMSCRAMMYes[25,35]
chpChemotaxis Inhibitory ProteinSExoproteinYes[22,23]
cnaCollagen AdhesinCWMSCRAMMYes[36]
eapExtracellular Adherence ProteinSSERAMYes[37]
ecbExtracellular Complement Binding ProteinSSERAMYes[19,38,39]
efbExtracellular Fibrinogen-Binding ProteinSSERAMYes[19,40,41]
empExtracellular Matrix ProteinSSERAMNo[42]
etaExfoliative Toxin ASEx. ToxinNo[28]
etbExfoliative Toxin BSEx. ToxinNo[28]
hlaα-hemolysin or Alpha ToxinSPF ToxinYes[43]
hlgγ-hemolysin or Gamma ToxinSPF ToxinYes[44]
lukAB/GHLeukocidin AB or Leukocidin GHSPF ToxinYes[44]
pvlPanton-Valentine LeukocidinSPF ToxinYes[24]
sakStaphylokinaseSProteaseYes[45]
sbiStaphylococcal Binder of ImmunoglobulinCW and SExoproteinYes[27,41,46]
scnStaphylococcal Complement InhibitorSExoproteinYes[21]
scpACysteine Protease Staphopain ASProteaseYes[47]
sdrCSerine-Aspartate Repeat Protein CCWMSCRAMMNo[48]
sdrDSerine-Aspartate Repeat Protein DCWMSCRAMMNo[49]
sdrESerine-Aspartate Repeat Protein ECWMSCRAMMYes[18,26]
seaStaphylococcal Enterotoxin ASEnterotoxin; SuperantigenYes[50]
sepStaphylococcal Enterotoxin PSEnterotoxinNo[51]
spAStaphylococcal Protein ACW and SExoproteinYes[52]
splBSerine Protease-Like Protein BSProteaseYes[53]
spnStaphylococcal Peroxidase InhibitorSExoproteinYes[54]
ssl7Staphylococcal Superantigen-Like 7 ProteinSExoproteinYes[55]
tstToxic Shock Syndrome ToxinSSuperantigenYes[29]
vwbvon Willebrand Factor-Binding ProteinSSERAMYes[19,56]
1 Type: secreted (S); cell-wall (CW). 2 Group: exfoliative toxin (Ex. Toxin); pore-forming toxin (PF Toxin).
Table 2. BD Phoenix panel.
Table 2. BD Phoenix panel.
Infection Type *
AntibioticRange (µg/mL)Blood/SSTIUrine
Clindamycin0.5–2XN/A
Erythromycin0.5–4XN/A
Gentamycin1–8XX
Oxacillin0.25–2XX
Penicillin G0.125–8XX
Rifampin0.5–2XX
Tetracycline0.5–8XX
Trimethoprim-
Sulfamethoxazole
0.5/9.5–2/38XX
Vancomycin0.5–16XX
Nitrofurantoin16–64 N/AX
* Isolates associated with various infection type (blood, SSTI, or urine) were subjected to antibiotics as indicated by the X symbol. N/A indicates test not performed.
Table 3. PCR primers used for VF identification.
Table 3. PCR primers used for VF identification.
GeneForward Primer (5′-3′)Reverse Primer (5′-3′)Ref.
bbpAACTACATCTAGTACTCAACAACAGATGTGCTTGAATAACACCATCATCT[62]
clfAATTGGCGTGGCTTCAGTGCTCGTTTCTTCCGTAGTTGCATTTG[62]
chpGGAATCAGTACACACCATCATTCAGATTTCTCAAACGTTCATCTAATTTTCC[63]
etbGTGGTAAAGGCGGACAACATTCAAATCGTTCCCCAAAGTG[64]
hlaTATAGTCAGCTCAGTAACAACAACATGCATGCCATTTTCTTTATCATAAGTGAC[63]
pvlATCATTAGGTAAAATGTCTGGACATGATCCAGCATCAAGTGTATTGGATAGCAAAAGC[65]
scn GTTGATATTTTGCTTCTGACAT AACGAAAAGTTAGCTAATGAAT[66]
sdrEAGAAAGTATACTGTAGGAACTGGATGGTTTTGTAGTTACATCGT[67]
spACAAACGGCACTACTGCTGACCATGGTTTGCTGGTTGCTTC[68]
Table 4. Sample pool composition.
Table 4. Sample pool composition.
CategorynIsolates
MRSA5444%
MSSA6856%
Blood1915.6%
SSTI9678.7%
Urine *75.8%
Blood MRSA108.2%
Blood MSSA97.4%
SSTI MRSA4436%
SSTI MSSA5242.6%
n = 122; * All urine samples were CA-MSSA.
Table 5. Genes with 100% carriage.
Table 5. Genes with 100% carriage.
GeneVFDescription of ActionRef.
clfAClumping Factor ABinds human fibrinogen, involved in biofilm formation and S. aureus-mediated platelet aggregation. Contributes to immune evasion by binding complement regulator Factor I.[25,35,75]
scpACysteine Protease Staphopain AProtease with inhibitory effects on complement pathways. Impairs phagocytosis by neutrophils.[47]
sbiStaphylococcal Binder of ImmunoglobulinBinds IgG Fc; binds and activates host plasminogen to intefere with complement-mediated opsonization.[27,41]
spAStaphylococcal
Protein A
Binds IgG Fc and cross-links the Fab domain of IgM to subvert opsonization and phagocytosis.[52]
vwbvon Willebrand Factor-Binding ProteinSecreted adhesin that binds to plasma components and induces blood clots. Assists in strengthening abscess walls.[56]
Table 6. Genes with significant variation due to methicillin resistance or infection type.
Table 6. Genes with significant variation due to methicillin resistance or infection type.
GeneVFDescription of ActionCarriage (%) *Ref.
chpChemotaxis Inhibitory ProteinInhibits fMLP- and C5a-induced chemotaxis of neutrophils and monocytes.All: 68;
85 R, 54 S;
74 SSTI, 47 B, 43 U
[22,23]
cnaCollagen AdhesinBinds host collagen. Inhibits complement by binding the initiator protein C1q.All: 19;
10 R, 26S
[36,76]
ecbExtra-cellular Complement Binding ProteinImpairs complement-mediated phagocytosis by binding complement C3b or C3, and reduces the cofactor activity of CR1.All: 82;
92 R, 74 S
[38,39]
pvlPanton-Valentine LeukocidinBi-component leukocidin that forms β-barrel pores in host cells, with high specificity to human neutrophils.All: 43;
70 R, 22 S;
52 SSTI, 16 B, 0 U
[24]
sakStaphylokinaseBinds and activates host plasminogen to break down host extracellular matrices. Also removes IgG and C3b (opsonins) from the bacterial surface.All: 89;
96 R, 84 S
[45]
splBSerine Protease-Like Protein BCleaves and inactivates several complement components, inhibiting all three pathways, reducing bacterial killing via phagocytosis.All: 79;
88 R, 72 S
[53]
seaStaphylococcal Enterotoxin ACommonly associated with food poisoning; causes emesis, diarrhea, and GI inflammation. Also known for nonspecific activation of T-cells, resulting in acute toxic shock.All: 8;
4 SSTI, 4 B, 29 U
[50,77]
sepStaphylococcal Enterotoxin PRelated to and often on the same pathogenicity island as sea, though produces much milder symptoms.All: 10;
5 SSTI, 35 B, 14 U
[51,78]
* Superscript denotes the following: resistance type: R MRSA, S MSSA; infection type: SSTI SSTI, B blood, U urine.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Cranmer, K.D.; Pant, M.D.; Quesnel, S.; Sharp, J.A. Clonal Diversity, Antibiotic Resistance, and Virulence Factor Prevalence of Community Associated Staphylococcus aureus in Southeastern Virginia. Pathogens 2024, 13, 25. https://doi.org/10.3390/pathogens13010025

AMA Style

Cranmer KD, Pant MD, Quesnel S, Sharp JA. Clonal Diversity, Antibiotic Resistance, and Virulence Factor Prevalence of Community Associated Staphylococcus aureus in Southeastern Virginia. Pathogens. 2024; 13(1):25. https://doi.org/10.3390/pathogens13010025

Chicago/Turabian Style

Cranmer, Katelyn D., Mohan D. Pant, Suzanne Quesnel, and Julia A. Sharp. 2024. "Clonal Diversity, Antibiotic Resistance, and Virulence Factor Prevalence of Community Associated Staphylococcus aureus in Southeastern Virginia" Pathogens 13, no. 1: 25. https://doi.org/10.3390/pathogens13010025

APA Style

Cranmer, K. D., Pant, M. D., Quesnel, S., & Sharp, J. A. (2024). Clonal Diversity, Antibiotic Resistance, and Virulence Factor Prevalence of Community Associated Staphylococcus aureus in Southeastern Virginia. Pathogens, 13(1), 25. https://doi.org/10.3390/pathogens13010025

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop